person · Reporting owner
SALEKI-GERHARDT AZITA
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF OPERATIONS OFFICER | February 27, 2026 | March 03, 2026 |
| ENTEGRIS INCENTG · Entity 3271 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 197,794 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 16,309 · Balance 197,794 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 2,706 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,706 F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse | 3,873 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,873 F2: The reporting person disclaims beneficial ownership of all securities held by her spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
F2: The reporting person disclaims beneficial ownership of all securities held by her spouse.
ENTEGRIS INC
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,383 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 1,412 · Balance 26,383 F1: These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2027 Annual Meeting of Stockholders. F2: These shares were awarded on May 6, 2026 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. |
Filing footnotes · ownership attribution and instrument terms
F1: These Restricted Stock Units vest in full on the earlier of (1) the first anniversary date of the grant, or (2) the date of the Company's 2027 Annual Meeting of Stockholders.
F2: These shares were awarded on May 6, 2026 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,464 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 25,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,896 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 74,520 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · derivative · entry 8 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,520 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 12,400 | $0.00 Strike: $29.23 | $0.00 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,400 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 9,057 | $116.70 | $1,056,996.28 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,284 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 77,863 | $116.24 | $9,051,036.50 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,341 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 74,520 | $35.88 | $2,673,777.60 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2021 Filed May 26, 2021 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 12,400 | $29.23 | $362,452.00 |
DisclosureSEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:12 UTC | ENTEGRIS INC ENTG · Entity 3271 | GrantCommon Stock | 1,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001101302-21-000048 · wf-form4_162007276626333.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,733 F1 · shares: These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2022 Annual Meeting of Stockholders. F2 · price: These shares were awarded on April 29, 2021 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:31 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 15,785 | $107.74 | $1,700,675.90 |
DisclosureSEC source: 0001179110-21-002605 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,284 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(right to buy) · Derivative | 42,236 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,236 Underlying: Common stock · 42,236 shares Expires 2031-02-17 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,079 on February 18, 2022, 14,079 on February 18, 2023, and 14,078 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,069 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,840 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,272 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 14,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,993 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:56 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 17,426 | $98.00 | $1,707,748.00 |
DisclosureSEC source: 0001179110-20-011059 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,441 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:29 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,800 | $93.61 | $449,328.00 |
DisclosureSEC source: 0001179110-20-010867 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,067 F1 · shares: This sale was made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| November 04, 2020 Filed Nov 12, 2020 22:55 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 4,800 | $0.00 Strike: $24.21 | $0.00 |
DisclosureSEC source: 0001179110-20-011058 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 04, 2020 Filed Nov 12, 2020 22:55 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,800 | $93.61 | $449,328.00 |
DisclosureSEC source: 0001179110-20-011058 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,867 Read SEC document |
| November 04, 2020 Filed Nov 12, 2020 22:55 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 4,800 | $24.21 | $116,199.36 |
DisclosureSEC source: 0001179110-20-011058 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:29 UTC | ENTEGRIS INC ENTG · Entity 3271 | GrantCommon Stock | 2,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001101302-20-000034 · wf-form4_158836493131363.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,123 F1 · shares: These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2021 Annual Meeting of Stockholders. F2 · price: These shares were awarded on April 29, 2020 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2020 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:56 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 16,342 | $85.42 | $1,395,933.64 |
DisclosureSEC source: 0001179110-20-002861 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,867 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 73,649 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002131 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,649 Underlying: Common Stock · 73,649 shares Expires 2030-02-19 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,550 on February 20, 2021, 24,550 on February 20, 2022, and 24,549 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,209 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,641 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,362 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 19,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002131 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,192 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:05 UTC | ENTEGRIS INC ENTG · Entity 3271 | GrantCommon Stock | 3,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001101302-19-000021 · wf-form4_155691390349252.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,556 F1 · shares: These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2020 Annual Meeting of Stockholders. F2 · price: These shares were awarded on May 1, 2019 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan, which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 15,797 | $79.03 | $1,248,479.56 |
DisclosureSEC source: 0001179110-19-003445 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,312 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.77 to $79.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:58 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,569 | $79.41 | $998,104.29 |
DisclosureSEC source: 0001179110-19-003089 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,109 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 34,267 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,267 Underlying: Common Stock · 34,267 shares Expires 2029-02-20 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,423 on February 21, 2020, 11,422 on February 21, 2021, and 11,422 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 4,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,678 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,397 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,227 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 9,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002365 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,147 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| May 09, 2018 Filed May 10, 2018 20:55 UTC | ENTEGRIS INC ENTG · Entity 3271 | GrantCommon Stock | 4,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001101302-18-000026 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,987 F1 · shares: These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2019 Annual Meeting of Stockholders. F2 · price: These shares were awarded on May 9, 2018 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:31 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,337 | $117.77 | $157,457.82 |
DisclosureSEC source: 0001179110-18-003339 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,312 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.74 to $117.792, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:31 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,683 | $118.26 | $1,499,891.58 |
DisclosureSEC source: 0001179110-18-003339 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,649 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 23,160 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · derivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,160 Underlying: Common Stock · 23,160 shares Expires 2028-02-14 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,720 on February 15, 2019, 7,720 on February 15, 2020, and 7,720 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,332 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 8,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,162 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,879 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 4,800 | $0.00 Strike: $24.21 | $0.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · derivative · entry 9 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 2,338 | $85.06 | $198,870.28 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,799 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,030 | $85.04 | $87,591.20 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,137 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 132 | $85.03 | $11,223.96 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,167 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 3,600 | $85.00 | $305,982.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,299 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,200 | $84.99 | $101,988.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,899 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 4,800 | $24.21 | $116,199.36 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 21:03 UTC | ENTEGRIS INC ENTG · Entity 3271 | GrantCommon Stock | 3,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001101302-17-000030 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,897 F1 · shares: These Restricted Stock Units vest in full on the earlier of (1) the anniversary date of the grant, or (2) the date of the Company's 2018 Annual Meeting of Stockholders. F2 · price: These shares were awarded on August 14, 2017 as Restricted Stock Units, payable solely in Common Stock, pursuant to the Entegris, Inc. 2010 Stock Plan which provides for the award of Restricted Stock Units to independent directors in consideration for services as such. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.